Every 424B that Artelo Biosciences, Inc. (ARTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ARTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTL filings page.
Artelo Biosciences, Inc. is offering up to $6,530,000 of common stock in an at-the-market program with H.C. Wainwright & Co., LLC as exclusive sales agent.
The sales agent will use commercially reasonable efforts to sell shares from time to time under an At the Market Offering Agreement dated May 26, 2026, and will receive a 3.0% commission. The offering is subject to Form S-3 resale limits under General Instruction I.B.6.
ARTL terminates its At-The-Market equity offering agreement effective May 18, 2026. The company had an ATM capacity of $6,500,000 and reports aggregate sales of 50,858 shares for gross proceeds of $451,526.95. The prospectus supplement ends the continuous offering under the ATM Prospectus.
The Sales Agreement with R.F. Lafferty & Co., Inc. was terminated by notice on May 11, 2026, effective May 18, 2026. The Common Stock trades on Nasdaq under the symbol ARTL; the last reported sales price on May 15, 2026 was $1.84.
Artelo Biosciences is registering up to 9,820,294 shares of Common Stock for resale. The shares consist of 81,000 issued shares, up to 3,107,407 shares issuable on Pre-Funded Warrants, up to 6,376,814 shares issuable on Common Warrants and up to 255,073 shares issuable on Placement Agent Warrants.
The Company is not selling any shares here and will not receive proceeds from resale by the Selling Stockholders; however, Artelo may receive up to $21,508,908.56 in gross proceeds if the Warrants and Placement Agent Warrants are exercised for cash. The prospectus discloses Beneficial Ownership Limitation provisions (4.99% or 9.99% election) and cashless-exercise conditions for certain Warrants.
ArteLo Biosciences, Inc. (ARTL) is offering an aggregate of 454,545 shares of common stock and associated Pre-funded Warrants. The Pre-funded Warrants have an exercise price of $0.001 per share and are immediately exercisable upon issuance until exercised in full. The prospectus supplement also notes Ordinary Shares that will be issuable upon exercise of those Pre-funded Warrants. Separately, the filing includes a brief scientific description that the CB1 receptor is distributed in brain regions tied to motor control, emotion, motivated behavior and energy homeostasis while the CB2 receptor is mainly expressed in the immune system and upregulated in response to tissue stress or damage.
Artelo Biosciences is launching a primary offering of common stock and pre-funded warrants under its existing $75 million shelf registration to raise cash for operations and drug development. The pre-funded warrants carry a nominal $0.001 exercise price and are structured to let larger investors participate without breaching 4.99% or 9.99% ownership caps. Artelo plans to use the proceeds to advance its cannabinoid‑based and lipid‑signaling product candidates through preclinical and clinical work, and for working capital and general corporate purposes.
The company is an early‑stage biotech with no mature products, recurring losses, and substantial doubt about its ability to continue as a going concern. It faces Nasdaq listing risk due to low stockholders’ equity and has recently undertaken highly dilutive financings and complex instruments, including prior private placements and a required purchase of Solana cryptocurrency, whose volatility could further strain liquidity.
The company filed a prospectus supplement under Rule 424(b)(5) to update its at-the-market common stock offering program with R.F. Lafferty & Co., Inc. The supplement reduces the maximum aggregate gross sales price of common stock that may be offered under the sales agreement from this point forward to $0, effectively suspending further sales under the existing ATM prospectus. The company previously registered up to $6,500,000 of common stock for this program, which was reduced to $3,451,527 on September 4, 2025, and all $451,527 of common stock that was available for sale under the amended ATM prospectus has now been sold. As of September 29, 2025, the aggregate market value of outstanding common stock held by non-affiliates was $18,399,248, based on 1,555,493 shares outstanding and a Nasdaq closing price of $11.86 on July 31, 2025.